A product of independent beta probabilities dose escalation design for dual-agent phase I trials.

ABSTRACT: Dual-agent trials are now increasingly common in oncology research, and many proposed dose-escalation designs are available in the statistical literature. Despite this, the translation from statistical design to practical application is slow, as has been highlighted in single-agent phase I trials, where a 3 + 3 rule-based design is often still used. To expedite this process, new dose-escalation designs need to be not only scientifically beneficial but also easy to understand and implement by clinicians. In this paper, we propose a curve-free (nonparametric) design for a dual-agent trial in which the model parameters are the probabilities of toxicity at each of the dose combinations. We show that it is relatively trivial for a clinician's prior beliefs or historical information to be incorp

SUBMITTER: Mander AP 

PROVIDER: S-EPMC4409822 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature